289 In the index

Rapamycin RAPA

An FDA-approved drug (sirolimus) used to prevent organ-transplant rejection, now a major focus of human aging research at much lower, occasional doses. Its approved transplant use is well proven; separate human studies and case reports on low-dose use for aging and immune health show promising early signs but remain experimental and off-label.

Also known as Sirolimus, Rapamune, (-)-Rapamycin, rapalimus, FYARRO, HYFTOR, sirolimusum

Effects Longevity

Routes Oral

Legal status Prescription drug

WADA Not listed

Molecular Structure of C₅₁H₇₉NO₁₃

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C51H79NO13
Molar mass: 914.2
CAS: 53123-88-9
PubChem CID: 5284616
IUPAC name: (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
InChIKey: QFJCIRLUMZQUOT-HPLJOQBZSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 1-6 mg once weekly (off-label longevity use)

Reported range 1-15 mg once weekly, or 2-5 mg/day (transplant, chronic dosing)

Route Oral

Frequency Once weekly (off-label longevity protocols) or once daily (approved transplant use)

Duration Chronic/ongoing (as prescribed) or intermittent long-term use (off-label longevity protocols)

FDA-approved immunosuppressant (Rapamune) for organ-transplant rejection prevention; low-dose, intermittent 'longevity' use is off-label, physician-directed in some practices, and not an FDA-approved indication.

Where this comes from FDA prescribing information; off-label clinical use patterns

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.